Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Publ. Version/Full Text
DOI
PMC
 |
Free by publisher |
: Postprint online available 10/2021
as soon as is submitted to ZB.
Therapeutic effectiveness of thalidomide in a patient with treatment-resistant restless legs syndrome.
J. Clin. Sleep Med. 16, 1815-1817 (2020)
Publ. Version/Full Text
DOI
PMC
None: Recent developments in the genetics of restless legs syndrome (RLS) revealed associations of disease risk with genetic loci containing the genes coding cereblon, the protein bound by thalidomide, and its endogenous substrate MEIS2, whose degradation is inhibited by the thalidomide-cereblon interaction. Therefore it was hypothesized that thalidomide may be a potential treatment option for RLS. Here we report on the therapeutic effect of thalidomide in a patient with otherwise treatment-resistant RLS who received 100 mg thalidomide off-label for 3 weeks. The female patient, severely affected by RLS before treatment, experienced significant amelioration of the symptoms, increased self-reported sleep quality, and better daytime functioning during thalidomide treatment. This therapeutic success warrants larger studies investigating the efficacy of drugs of the thalidomide class in RLS.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Case Report ; Restless Legs Syndrome ; Thalidomide ; Treatment; Validation; Daytime; Scale
ISSN (print) / ISBN
1550-9389
e-ISSN
1550-9397
Quellenangaben
Volume: 16,
Issue: 10,
Pages: 1815-1817
Publisher
American Academy of Sleep Medicine and the Sleep Research Society
Publishing Place
Darien, IL
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Neurogenomics (ING)